People · Operator
Named in public records as an officer, director or promoter · active 2015–2025 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Inhibrx, Inc. | — | Biotechnology | Growth/Late | $668.6M | $3.3B | 2020 |
| ADARx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $352.5M | $2.8B | 2023 |
| Avenzo Therapeutics, Inc. | — | Biotechnology | Series D+ | $270.6M | $355.7M | 2022 |
| Tmunity Therapeutics, Inc. | — | Biotechnology | Series C | $175.0M | $3.1B | 2018 |
| E-scape Bio, Inc. | — | Biotechnology | Series C | $167.1M | $2.8B | 2015 |
| NextCure, Inc. | — | Biotechnology | Series C | $129.9M | $113.9M | 2018 |
| Gritstone bio, Inc. | — | Biotechnology | Series C | $100.0M | $763.5M | 2021 |
| Veritas Genetics International Ltd. | — | Other Technology | Series B | $30.3M | $141.4M | 2016 |
Judith Li at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Judith Li on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 2 | 24 |
| Simeon George | 2 | 8 |
| Garry Nicholson | 2 | 3 |
| Asish Xavier | 1 | 18 |
| Peter Thompson | 1 | 16 |
| Beth Seidenberg | 1 | 15 |
| LEON CHEN | 1 | 15 |
| Patrick Gray | 1 | 10 |
| Sean Parker | 1 | 10 |
| David Kabakoff | 1 | 7 |
| Chen Yu | 1 | 7 |
| Erez Chimovits | 1 | 7 |
| Peter Moldt | 1 | 6 |
| Peter Parker | 1 | 6 |
| Lorence Kim | 1 | 5 |
| Sheila Gujrathi | 1 | 5 |
| Eric Shiozaki | 1 | 4 |
| Michael Yi | 1 | 4 |
| Andrew Allen | 1 | 4 |
| Hongbo Lu | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.